These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 11796175)
1. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Vichayanrat A; Ploybutr S; Tunlakit M; Watanakejorn P Diabetes Res Clin Pract; 2002 Feb; 55(2):99-103. PubMed ID: 11796175 [TBL] [Abstract][Full Text] [Related]
2. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. Lee MY; Choi DS; Lee MK; Lee HW; Park TS; Kim DM; Chung CH; Kim DK; Kim IJ; Jang HC; Park YS; Kwon HS; Lee SH; Shin HK J Korean Med Sci; 2014 Jan; 29(1):90-7. PubMed ID: 24431911 [TBL] [Abstract][Full Text] [Related]
3. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704 [TBL] [Abstract][Full Text] [Related]
4. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118 [TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes. Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258 [TBL] [Abstract][Full Text] [Related]
6. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461 [TBL] [Abstract][Full Text] [Related]
7. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152 [TBL] [Abstract][Full Text] [Related]
8. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]. Yamada K Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088 [TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329 [TBL] [Abstract][Full Text] [Related]
11. Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure? Nagai Y; Hayakawa T; Abe T; Nomura G Diabetes Care; 2000 Nov; 23(11):1703. PubMed ID: 11092296 [No Abstract] [Full Text] [Related]
12. Comparison of the effects of acarbose and voglibose in healthy subjects. Kageyama S; Nakamichi N; Sekino H; Nakano S Clin Ther; 1997; 19(4):720-9. PubMed ID: 9377616 [TBL] [Abstract][Full Text] [Related]
13. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Scheen AJ Drugs; 2003; 63(10):933-51. PubMed ID: 12699398 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W; J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Hirose T; Miyashita Y; Takagi M; Sumitani S; Kouhara H; Kasayama S Diabetes Res Clin Pract; 2001 Oct; 54(1):9-15. PubMed ID: 11532325 [TBL] [Abstract][Full Text] [Related]
16. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Mertes G Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089 [TBL] [Abstract][Full Text] [Related]
18. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial. Wu QL; Liu YP; Lu JM; Wang CJ; Yang T; Dong JX; Li CJ; Ma JH; Xue YM; Sun RH; Wei D; Tian HM J Evid Based Med; 2012 Aug; 5(3):134-8. PubMed ID: 23672220 [TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]